Company intelligence / Profile preview

NuView Life Sciences

Park City, Utah, United Statesnuviewlifesciences.com ↗

Ownership: Private
Employees: ~25
Development stage: Clinical

Overview

NuView's lead platform, NV-VPAC1, has demonstrated high specificity for cancer diagnostics and therapy delivery in multiple pre-clinical and early clinical settings, including Phase 1 data in breast cancer and ongoing/proposed studies in prostate and other cancers. The company's paired radiopharmaceuticals (Cu-64 and Cu-67) support both imaging and treatment. The products aim to distinguish malignant from benign lesions and have been shown to avoid detection of non-malignant lesions in both animal models and early human data[2][3][5][4].

Therapeutic areas: OncologyEndocrinologyWomen's Health
Modalities: Small moleculeRadiopharmaceuticalPeptides
Industry: Biotech

Drug pipeline

3 assets

NV-VPAC1

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NuView Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuView Life Sciences.

Explore the full profile